Abstract
The repurposing of FDA-approved Bruton's tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemothera......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
